{"title":"Direct triangular comparison of tissue and serum growth differentiation factor 15 with host factors in colorectal cancer.","authors":"Shinji Yamashita, Yoshinaga Okugawa, Koki Higashi, Yuki Sato, Takashi Ichikawa, Ryo Uratani, Takahito Kitajima, Tadanobu Shimura, Hiroki Imaoka, Mikio Kawamura, Yuhki Koike, Hiromi Yasuda, Shigeyuki Yoshiyama, Yoshiki Okita, Masaki Ohi, Yuji Toiyama","doi":"10.62347/WTCF3616","DOIUrl":null,"url":null,"abstract":"<p><p>Growth differentiation factor 15 (GDF-15) is a potential biomarker for colorectal cancer (CRC) and is associated with sarcopenia and cachexia. However, its clinical significance in CRC remains unclear. We investigated the clinical significance of GDF-15 in CRC patients by a unique triangular comparison of tissue and preoperative serum GDF-15 levels with host factors. We evaluated 428 tissue and 214 serum samples from 214 CRC patients. We measured tissue and serum levels of GDF-15 and assessed their association with oncological outcomes and host factors. While cancer tissue GDF-15 levels showed no significant associations with clinicopathological factors or survival, preoperative serum GDF-15 levels were significantly correlated with indicators of disease progression, such as advanced T stage and advanced pathological stage. High preoperative serum GDF-15 level was associated with poor disease-free survival and overall survival and was an independent prognostic factor for disease-free survival and overall survival. Significant correlations were observed between preoperative serum GDF-15 levels and host factors, including body mass index, psoas muscle mass index, intramuscular adipose tissue content, and C-reactive protein. In conclusion, preoperative serum GDF-15 reflects host factors such as body composition and inflammation and is a useful marker for the oncological management of CRC patients.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1174-1188"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982732/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/WTCF3616","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Growth differentiation factor 15 (GDF-15) is a potential biomarker for colorectal cancer (CRC) and is associated with sarcopenia and cachexia. However, its clinical significance in CRC remains unclear. We investigated the clinical significance of GDF-15 in CRC patients by a unique triangular comparison of tissue and preoperative serum GDF-15 levels with host factors. We evaluated 428 tissue and 214 serum samples from 214 CRC patients. We measured tissue and serum levels of GDF-15 and assessed their association with oncological outcomes and host factors. While cancer tissue GDF-15 levels showed no significant associations with clinicopathological factors or survival, preoperative serum GDF-15 levels were significantly correlated with indicators of disease progression, such as advanced T stage and advanced pathological stage. High preoperative serum GDF-15 level was associated with poor disease-free survival and overall survival and was an independent prognostic factor for disease-free survival and overall survival. Significant correlations were observed between preoperative serum GDF-15 levels and host factors, including body mass index, psoas muscle mass index, intramuscular adipose tissue content, and C-reactive protein. In conclusion, preoperative serum GDF-15 reflects host factors such as body composition and inflammation and is a useful marker for the oncological management of CRC patients.
期刊介绍:
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.